GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » PS Ratio

InflaRx NV (InflaRx NV) PS Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InflaRx NV's share price is $1.33. InflaRx NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, InflaRx NV's PS Ratio for today is .

The historical rank and industry rank for InflaRx NV's PS Ratio or its related term are showing as below:

IFRX' s PS Ratio Range Over the Past 10 Years
Min: 1280   Med: 1545   Max: 2610
Current: 1330

During the past 9 years, InflaRx NV's highest PS Ratio was 2610.00. The lowest was 1280.00. And the median was 1545.00.

IFRX's PS Ratio is ranked worse than
97.08% of 992 companies
in the Biotechnology industry
Industry Median: 8.85 vs IFRX: 1330.00

InflaRx NV's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Back to Basics: PS Ratio


InflaRx NV PS Ratio Historical Data

The historical data trend for InflaRx NV's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV PS Ratio Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only - - - - 1,630.00

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InflaRx NV's PS Ratio

For the Biotechnology subindustry, InflaRx NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's PS Ratio distribution charts can be found below:

* The bar in red indicates where InflaRx NV's PS Ratio falls into.



InflaRx NV PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

InflaRx NV's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.33/0.001
=

InflaRx NV's Share Price of today is $1.33.
InflaRx NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


InflaRx NV  (NAS:IFRX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


InflaRx NV PS Ratio Related Terms

Thank you for viewing the detailed overview of InflaRx NV's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines

From GuruFocus

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022